TY - JOUR
T1 - A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression
AU - Kye, Christopher H.
AU - Waterman, G. Scott
AU - Ryan, Neal D.
AU - Birmaher, Boris
AU - Williamson, Douglas E.
AU - Iyengar, Satish
AU - Dachille, Susan
N1 - Funding Information:
Accepted March 8, 1996. All authors are at the University of Pittsburgh Medical Center exceptfOr Dr. Watennan, who is at the University of Vennont, Burlington. This study was supported by NIMH grant R01 MH41647 to Dr. Ryan. Reprint requests to Dr. Ryan, Joaquim Puig-Antich Professor of Child Psychiatry, UniversityofPittsburghMedical Center, 3811 O'Hara, Pittsburgh, PA 15213. 0890-8567/96/3509-1139$03.00/0©1996 by the American Academy of Child and Adolescenr Psychiatry.
PY - 1996/9
Y1 - 1996/9
N2 - Objective: To determine amitriptyline's (AMI) efficacy in the acute treatment of adolescent major depressive disorder (MDD). Method: Subjects aged 12 through 17 years meeting Research Diagnostic Criteria for MDD, diagnosed with the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), participated in a 2-week placebo-washout followed by an 8-week, randomized, double-blind, parallel-design, placebo- controlled trial of AMI, 5 mg/kg per day. The K-SADS nine-item scale, the Hamilton Depression Rating Scale, and the Clinical Global Impressions rating scale were used as outcome measures. Results: Thirty-one subjects were randomized (18 AMI, 13 placebo). Twenty-two subjects were study completers (12 AMI, 10 placebo). AMI's efficacy was suggested by the Clinical Global Impressions but not the K-SADS-derived data. Perhaps the primary limitation of the current study is its small sample size. Conclusion: No definitive recommendation can be made regarding the efficacy of tricylic antidepressants in the treatment of adolescent MDD.
AB - Objective: To determine amitriptyline's (AMI) efficacy in the acute treatment of adolescent major depressive disorder (MDD). Method: Subjects aged 12 through 17 years meeting Research Diagnostic Criteria for MDD, diagnosed with the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), participated in a 2-week placebo-washout followed by an 8-week, randomized, double-blind, parallel-design, placebo- controlled trial of AMI, 5 mg/kg per day. The K-SADS nine-item scale, the Hamilton Depression Rating Scale, and the Clinical Global Impressions rating scale were used as outcome measures. Results: Thirty-one subjects were randomized (18 AMI, 13 placebo). Twenty-two subjects were study completers (12 AMI, 10 placebo). AMI's efficacy was suggested by the Clinical Global Impressions but not the K-SADS-derived data. Perhaps the primary limitation of the current study is its small sample size. Conclusion: No definitive recommendation can be made regarding the efficacy of tricylic antidepressants in the treatment of adolescent MDD.
KW - adolescent
KW - major depression
KW - treatment
KW - tricyclic antidepressant
UR - http://www.scopus.com/inward/record.url?scp=0029788087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029788087&partnerID=8YFLogxK
U2 - 10.1097/00004583-199609000-00011
DO - 10.1097/00004583-199609000-00011
M3 - Article
C2 - 8824057
AN - SCOPUS:0029788087
SN - 0890-8567
VL - 35
SP - 1139
EP - 1144
JO - Journal of the American Academy of Child Psychiatry
JF - Journal of the American Academy of Child Psychiatry
IS - 9
ER -